EMT-induced metabolite signature identifies poor clinical outcome

• Published in: Oncotarget 2015-12, Vol.6 (40), p.42651-42660
• Main Authors: Bhowmik, Salil Kumar, Ramirez-Peña, Esmeralda, Arnold, James Michael, Putluri, Vasanta, Sphyris, Nathalie, Michailidis, George, Putluri, Nagireddy, Ambs, Stefan, Sreekumar, Arun, Mani, Sendurai A
• Format: Article
• Language: English
• Subjects: Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Line, Tumor; Chromatography, High Pressure Liquid; Epithelial-Mesenchymal Transition - physiology; Female; Humans; Mass Spectrometry; Metabolome - physiology; Metabolomics - methods; Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.4765

Metabolic reprogramming is a hallmark of cancer. Epithelial-mesenchymal transition (EMT) induces cancer stem cell (CSC) characteristics and promotes tumor invasiveness; however relatively little is known about the metabolic reprogramming in EMT. Here we show that breast epithelial cells undergo metabolic reprogramming following EMT. Relative to control, cell lines expressing EMT transcription factors show ≥1.5-fold accumulation of glutamine, glutamate, beta-alanine and glycylleucine as well as ≥1.5-fold reduction of phosphoenolpyruvate, urate, and deoxycarnitine. Moreover, these metabolic alterations were found to be predictive of overall survival (hazard ratio = 2.3 (95% confidence interval: 1.31-4.2), logrank p-value = 0.03) and define breast cancer molecular subtypes. EMT-associated metabolites are primarily composed of anapleurotic precursors, suggesting that cells undergoing EMT have a shift in energy production. In summary, we describe a unique panel of metabolites associated with EMT and demonstrate that these metabolites have the potential for predicting clinical and biological characteristics associated with patient survival.